The yin and yang of cytokine priming on the macrophage epigenome

See allHide authors and affiliations

Science Immunology  03 Nov 2017:
Vol. 2, Issue 17, eaaq0016
DOI: 10.1126/sciimmunol.aaq0016


TNF and type I interferons alter TLR4 responses by reprogramming the macrophage genome.

Cytokines influence macrophage inflammatory responses; however, specific mechanisms involved remain unknown. Cytokine exposure has a broad impact on immune responses to infections and autoimmune diseases. Type I interferons (IFN-I) enhance antiviral activity and systemic lupus erythematosus (SLE) disease activity, whereas IFN-I ameliorate multiple sclerosis. Tumor necrosis factor (TNF) antagonizes the effects of IFN-I in SLE and promotes inflammation in rheumatoid arthritis (RA) and Crohn’s disease.

The article by Park et al. describes how TNF and IFN-I alter Toll-like receptor 4 (TLR4) responses by reprogramming the macrophage epigenome. These studies assessed the effects of pretreatment with TNF on lipopolysaccharide (LPS)–stimulated human macrophages and examined chromatin remodeling and gene expression by RNA-sequencing, chromatin immunoprecipitation sequencing, and assay for transposase-accessible chromatin sequencing. TNF pretreatment of macrophages altered gene expression responses, which were categorized into six groups. TNF induced “cross-tolerance” of nuclear factor κB (NFκB)-induced and inflammatory groups, the IFN-I group was nontolerized, whereas LPS and TNF synergized to induce the small molecule-lipid-metabolic group.

TNF-induced tolerance substantially blocked TLR4-induced gene expression. Histone marks and promoter/enhancer studies suggested that TNF altered chromatin to suppress gene expression of NFκB-induced and inflammatory groups. TNF tolerance differed from endotoxin tolerance as there was no inhibition of the IFN-I and small molecule-lipid-metabolic groups.

LPS-induced transcripts were analyzed in monocytes collected from patients with sepsis and after recovery. Patient monocyte transcriptional profile patterns were similar to TNF tolerance-induced profiles, which were reversed after patient recovery. Consistent with these effects, RA synovial macrophages expressed elevated levels of transcripts from nontolerized genes.

IFN-I added together with TNF restored expression of several LPS-inducible genes but did not reverse tolerization of TNF and IL6 genes. IFN-I did not affect TLR4 proximal signaling events, including expression of noncanonical NFκB molecules, suggesting a role for IFN-I downstream, in the nucleus. IFN-I pretreatment inhibited interleukin-10-mediated suppression of LPS-induced IL6 and related genes. Gene expression of ex vivo LPS-stimulated SLE monocytes correlated with that observed in IFN-I–treated TNF-tolerized monocytes.

In summary IFN-1 prime chromatin to facilitate vigorous transcriptional responses to weak stimulation and prevent TNF cross-tolerance. These studies elucidate cytokine-mediated mechanisms that integrate with TLR4 signaling to alter the epigenome and result in the functional reprogramming of macrophage inflammatory gene expression.

Highlighted Article

Stay Connected to Science Immunology

Navigate This Article